GSK PLC SP. ADR/2 NEW Capital Reinvestment Ratio
GSK PLC SP. ADR/2 NEW capital reinvestment ratio. GSK PLC SP. ADR/2 NEW (GS70) has a Capital Reinvestment Ratio of 0.24x as of June 2026, meaning it reinvests 0% of its operating cash flow (€2.69 Billion) in capital expenditures (€653.00 Million). Check GS70 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of GSK PLC SP. ADR/2 NEW (2021–2025)
Capital reinvestment ratio of GSK PLC SP. ADR/2 NEW from 2021 to 2025. This chart tracks GSK PLC SP. ADR/2 NEW's Capital Reinvestment Ratio across 5 annual periods. Also explore net asset momentum of GSK PLC SP. ADR/2 NEW to track the company's year-over-year net asset growth rate.
GSK PLC SP. ADR/2 NEW Capital Reinvestment Ratio by Year (2021–2025)
GSK PLC SP. ADR/2 NEW capital reinvestment ratio by year from 2021 to 2025. For the full cash flow conversion analysis, see GSK PLC SP. ADR/2 NEW operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | €7.74 Billion | €2.98 Billion | ▼ -15.2% |
| 2024 | 0.45x | €6.55 Billion | €2.98 Billion | ▲ +31.4% |
| 2023 | 0.35x | €6.77 Billion | €2.34 Billion | ▲ +13.5% |
| 2022 | 0.31x | €7.40 Billion | €2.26 Billion | ▼ -8.6% |
| 2021 | 0.33x | €7.95 Billion | €2.65 Billion | — |